{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:45Z","timestamp":1786119045606,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/hco.0b013e32831ac90b","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T03:13:46Z","timestamp":1228965226000},"page":"88-94","source":"Crossref","is-referenced-by-count":6,"title":["Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina\/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?"],"prefix":"10.1097","volume":"24","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210204","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacc.2005.11.025","article-title":"ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R2-14-20210204","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 Randomized Trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"J Am Med Assoc"},{"key":"R3-14-20210204","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.CIR.82.4.1193","article-title":"Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group","volume":"82","author":"Ellis","year":"1990","journal-title":"Circulation"},{"key":"R4-14-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9149(03)00655-6","article-title":"Evaluation of the American College of Cardiology\/American Heart Association and the Society for Coronary Angiography and Interventions Lesion Classification System in the current \u2018Stent Era\u2019 of coronary interventions (from the ACC-National Cardiovascular Data Registry)","volume":"92","author":"Krone","year":"2003","journal-title":"Am J Cardiol"},{"key":"R5-14-20210204","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jcin.2007.12.006","article-title":"Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the mayo clinic from 1994 to 2005","volume":"1","author":"Doyle","year":"2008","journal-title":"J Am Coll Cardiol Intv"},{"key":"R6-14-20210204","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1161\/01.CIR.0000017635.82128.8C","article-title":"Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb\/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial","volume":"105","author":"Stone","year":"2002","journal-title":"Circulation"},{"key":"R7-14-20210204","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1161\/01.CIR.0000028335.31300.DA","article-title":"Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial","volume":"106","author":"Holmes","year":"2002","journal-title":"Circulation"},{"key":"R8-14-20210204","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1067\/mhj.2002.120770","article-title":"The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2)","volume":"143","author":"Tamai","year":"2002","journal-title":"Am Heart J"},{"key":"R9-14-20210204","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0002-8703(99)70025-6","article-title":"Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT)","volume":"138","author":"Tamai","year":"1999","journal-title":"Am Heart J"},{"key":"R10-14-20210204","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1067\/mhj.2003.56","article-title":"Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years","volume":"145","author":"Marso","year":"2003","journal-title":"Am Heart J"},{"key":"R11-14-20210204","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-9149(02)02560-2","article-title":"Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb\/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)","volume":"90","author":"Labinaz","year":"2002","journal-title":"Am J Cardiol"},{"key":"R12-14-20210204","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"R13-14-20210204","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jacc.2005.05.084","article-title":"Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative","volume":"461","author":"Alexander","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R14-14-20210204","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"R15-14-20210204","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"J Am Med Assoc"},{"key":"R16-14-20210204","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1161\/CIRCULATIONAHA.107.182615","article-title":"Acute coronary care in the elderly. Part I: Non-ST-segment\u2013elevation acute coronary syndromes. A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology in collaboration with the Society of Geriatric Cardiology","volume":"115","author":"Alexander","year":"2007","journal-title":"Circulation"},{"key":"R17-14-20210204","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jacc.2004.11.055","article-title":"Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology\/American Heart Association Guidelines) National Quality Improvement Initiative","volume":"45","author":"Blomkalns","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R18-14-20210204","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.106.620815","article-title":"Sex differences in major bleeding with glycoprotein IIb\/IIIa inhibitors results from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC\/AHA Guidelines) Initiative","volume":"114","author":"Alexander","year":"2006","journal-title":"Circulation"},{"key":"R19-14-20210204","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1161\/01.CIR.102.24.2966","article-title":"Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?","volume":"102","author":"Rubenstein","year":"2000","journal-title":"Circulation"},{"key":"R20-14-20210204","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/heart.89.9.1003","article-title":"Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE)","volume":"89","author":"Santopinto","year":"2003","journal-title":"Heart"},{"key":"R21-14-20210204","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.amjcard.2004.11.003","article-title":"Bivalirudin versus heparin and glycoprotein IIb\/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)","volume":"95","author":"Chew","year":"2005","journal-title":"Am J Cardiol"},{"key":"R22-14-20210204","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0735-1097(02)02956-X","article-title":"Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb\/IIIa inhibitors","volume":"41","author":"Freeman","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R24-14-20210204","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.jacc.2005.09.080","article-title":"Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial","volume":"47","author":"Kirtane","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R25-14-20210204","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0735-1097(02)02119-8","article-title":"Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes","volume":"40","author":"Kleiman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R26-14-20210204","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2006.04.102","article-title":"Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality","volume":"48","author":"Prasad","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R27-14-20210204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"R28-14-20210204","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N Engl J Med"},{"key":"R30-14-20210204","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"J Am Med Assoc"},{"key":"R31-14-20210204","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.289.7.903","article-title":"Should bivalirudin replace heparin during percutaneous coronary interventions?","volume":"289","author":"Antman","year":"2003","journal-title":"J Am Med Assoc"},{"key":"R32-14-20210204","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"key":"R35-14-20210204","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention","volume":"100","author":"Boersma","year":"1999","journal-title":"Circulation"},{"key":"R36-14-20210204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0735-1097(03)00514-X","article-title":"Early use of glycoprotein IIb\/IIIa inhibitors in non-ST elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4","volume":"42","author":"Peterson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R37-14-20210204","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes. The ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R38-14-20210204","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","article-title":"The Early Glycoprotein IIb\/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome \u2013 study design and rationale","volume":"149","author":"Giugliano","year":"2005","journal-title":"Am Heart J"},{"key":"R39-14-20210204","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.1161\/ATVBAHA.107.160689","article-title":"P2Y12 antagonism: promises and challenges","volume":"28","author":"Michelson","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R40-14-20210204","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HCO.0b013e32831ac90b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:26:20Z","timestamp":1786037180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001573-200901000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e32831ac90b","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}